Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
about
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialTreatment of hemophilia: a review of current advances and ongoing issuesThe effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophiliaSecondary prophylaxis in adolescent and adult haemophiliacs.Unnecessary Hysterectomy due to Menorrhagia and Disorders of Hemostasis: An Example of Overuse and Excessive Demand for Medical Services.Prophylaxis use among males with haemophilia B in the United States.Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.Prevention of haemophilic synovitis: prophylaxis.Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
P2860
Q34737483-B5C4F419-B529-41E1-951C-8547AB9ECAECQ35683781-C38FEFA0-AF7F-4950-876E-63FBB1A1774FQ35826358-C5B00C54-3E8E-4022-9DF8-3101A9A02A7EQ37119647-FCD5B478-11F6-4C78-B885-4107C08E6C5BQ37528592-9093BE89-16F6-4E03-8C4D-C02F378EF920Q38638489-500BD444-9D0C-4FB6-9393-67794B4D76B5Q41772358-7F6B3648-2C8D-4511-98F6-2D935ABC7107Q45856031-7DE140B1-6A0A-4679-8856-50B4DD4CFB92Q45870783-FCF5B9DE-0556-4EA7-950D-3DC6492FD638Q45872785-E792212B-CC86-4636-9B61-ADD5658FBB6D
P2860
Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Assessing the effectiveness an ...... vere von Willebrand's disease.
@en
Assessing the effectiveness an ...... vere von Willebrand's disease.
@nl
type
label
Assessing the effectiveness an ...... vere von Willebrand's disease.
@en
Assessing the effectiveness an ...... vere von Willebrand's disease.
@nl
prefLabel
Assessing the effectiveness an ...... vere von Willebrand's disease.
@en
Assessing the effectiveness an ...... vere von Willebrand's disease.
@nl
P2093
P1476
Assessing the effectiveness an ...... vere von Willebrand's disease.
@en
P2093
P304
P356
10.1046/J.1365-2796.1998.00396.X
P407
P577
1998-12-01T00:00:00Z